NCT00100282

Data

{
  "briefSummary": "This is a multi-center, double-blind, inpatient study followed by outpatient, placebo-controlled, single-dose, dose-escalation evaluation of the safety and tolerability of PPI-1019 in patients with mild-moderate Alzheimer's disease (AD). Up to 12 sequential cohorts of 8 patients (6 active and 2 placebo) will be given a single PPI-1019 dose intravenously (IV) over 1 minute in order to determine a maximum tolerated dose (MTD). The MTD will be the dose immediately below the not-tolerated dose.",
  "completionDate": "2005-06",
  "conditions": [
    "Alzheimer's Disease"
  ],
  "enrollmentCount": 125,
  "enrollmentType": null,
  "nctId": "NCT00100282",
  "phase": "PHASE1",
  "sponsorId": "praecis-pharmaceuticals-inc",
  "startDate": "2003-05",
  "status": "COMPLETED",
  "studyType": "INTERVENTIONAL",
  "title": "Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease",
  "url": "https://clinicaltrials.gov/study/NCT00100282"
}

History in this collection

1. addedv1.0.0Jun 12, 2026this version